FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128665037> ?p ?o ?g. }

• W3128665037 endingPage "106523" @default.
• W3128665037 startingPage "106523" @default.
• W3128665037 abstract "Abstract Introduction Chronic Myeloid Leukemia (CML) is a hematological disease which is characterized by the presence of BCR-ABL fusion protein. Imatinib (IMA), a tyrosine kinase inhibitor of BCR-ABL, is used as a frontline treatment.Although IMA aids in killing a majority of leukemia cells, it may not kill CML stem cells which are the primary roots of disease and therapy resistance. Recently, antimicrobial drugs have been gaining attention because of their selective targeting of cancer cells. Therefore, we now ask if combinational therapy of IMA with a targeted antimicrobial drug Azithromycin (AZT) can enhance the treatment efficiency in IMA resistant CML. Methods K562S (IMA sensitive) and K562R (IMA resistant) cells were treated with increasing concentrations of AZT to determine its effects on cell proliferation and apoptosis. Cell viability, apoptosis, caspase3/7 activity and P-glycoprotein (Pgp) function were investigated with spectrophotometric MTT assay and flow cytometric Annexin V staining, caspase 3/7 activity, and Rhodamine123 staining assays respectively. The expression levels of pro-apoptotic (BAX, BAD and BIM), anti- apoptotic (BCL-XL and BCL-2) and drug transporter (MDR-1 and MRP-1) genes were assessed with qRT-PCR. Results AZT treatment alone inhibited cell viability, induced apoptosis and enhanced caspase 3/7 activity in both K562S and high MDR-1 (Pgp) expressing K562R cells. Moreover, combination of AZT/IMA suppressed cell viability, induced apoptosis and caspase3/7 activity more effectively and significantly compared to K562R cells treated with only IMA or AZT. Furthermore, AZT and AZT/IMA combination decreased Pgp function in K562R cells in comparison with their controls. Based on qRT-PCR data, single AZT and combined AZT/IMA treatment also induced BAX/BCL-2 ratio significantly in both K562S and K562R cells. Conclusion Single AZT and AZT/IMA combinational treatment can be proposed as a promising and effective treatment strategy for CML. One of the mechanisms underlying the potent anticancer effect of combined AZT/IMA could be its ability to inhibit Pgp function and increase intracellular accumulation of IMA which leads to the induction of apoptosis in K562R cells." @default.
• W3128665037 created "2021-02-15" @default.
• W3128665037 creator A5012037946 @default.
• W3128665037 creator A5028540373 @default.
• W3128665037 creator A5030100720 @default.
• W3128665037 creator A5041077415 @default.
• W3128665037 creator A5049124047 @default.
• W3128665037 creator A5058144610 @default.
• W3128665037 creator A5064235138 @default.
• W3128665037 date "2021-03-01" @default.
• W3128665037 modified "2023-10-18" @default.
• W3128665037 title "Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells" @default.
• W3128665037 cites W1707356941 @default.
• W3128665037 cites W1897724420 @default.
• W3128665037 cites W1973702720 @default.
• W3128665037 cites W2002643278 @default.
• W3128665037 cites W2005813259 @default.
• W3128665037 cites W2006917576 @default.
• W3128665037 cites W2024437663 @default.
• W3128665037 cites W2033870734 @default.
• W3128665037 cites W2055823135 @default.
• W3128665037 cites W2056025136 @default.
• W3128665037 cites W2061497413 @default.
• W3128665037 cites W2062781024 @default.
• W3128665037 cites W2069699348 @default.
• W3128665037 cites W2090591722 @default.
• W3128665037 cites W2105267564 @default.
• W3128665037 cites W2110370973 @default.
• W3128665037 cites W2131689043 @default.
• W3128665037 cites W2136679767 @default.
• W3128665037 cites W2274289318 @default.
• W3128665037 cites W2322652491 @default.
• W3128665037 cites W2384171741 @default.
• W3128665037 cites W2416095274 @default.
• W3128665037 cites W2463718936 @default.
• W3128665037 cites W2552110868 @default.
• W3128665037 cites W2556219113 @default.
• W3128665037 cites W2569248253 @default.
• W3128665037 cites W2586609287 @default.
• W3128665037 cites W2589028645 @default.
• W3128665037 cites W2729738977 @default.
• W3128665037 cites W2782479643 @default.
• W3128665037 cites W2806207913 @default.
• W3128665037 cites W2810131406 @default.
• W3128665037 cites W2892978381 @default.
• W3128665037 cites W2911580497 @default.
• W3128665037 cites W2935744167 @default.
• W3128665037 cites W2948000964 @default.
• W3128665037 cites W2949029991 @default.
• W3128665037 cites W2970379080 @default.
• W3128665037 cites W2977842153 @default.
• W3128665037 cites W4252180902 @default.
• W3128665037 cites W4293528792 @default.
• W3128665037 doi "https://doi.org/10.1016/j.leukres.2021.106523" @default.
• W3128665037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33607534" @default.
• W3128665037 hasPublicationYear "2021" @default.
• W3128665037 type Work @default.
• W3128665037 sameAs 3128665037 @default.
• W3128665037 citedByCount "10" @default.
• W3128665037 countsByYear W31286650372022 @default.
• W3128665037 countsByYear W31286650372023 @default.
• W3128665037 crossrefType "journal-article" @default.
• W3128665037 hasAuthorship W3128665037A5012037946 @default.
• W3128665037 hasAuthorship W3128665037A5028540373 @default.
• W3128665037 hasAuthorship W3128665037A5030100720 @default.
• W3128665037 hasAuthorship W3128665037A5041077415 @default.
• W3128665037 hasAuthorship W3128665037A5049124047 @default.
• W3128665037 hasAuthorship W3128665037A5058144610 @default.
• W3128665037 hasAuthorship W3128665037A5064235138 @default.
• W3128665037 hasConcept C126322002 @default.
• W3128665037 hasConcept C143998085 @default.
• W3128665037 hasConcept C2777583451 @default.
• W3128665037 hasConcept C2778729363 @default.
• W3128665037 hasConcept C2778907293 @default.
• W3128665037 hasConcept C501593827 @default.
• W3128665037 hasConcept C502942594 @default.
• W3128665037 hasConcept C71924100 @default.
• W3128665037 hasConcept C86803240 @default.
• W3128665037 hasConcept C89423630 @default.
• W3128665037 hasConcept C98274493 @default.
• W3128665037 hasConceptScore W3128665037C126322002 @default.
• W3128665037 hasConceptScore W3128665037C143998085 @default.
• W3128665037 hasConceptScore W3128665037C2777583451 @default.
• W3128665037 hasConceptScore W3128665037C2778729363 @default.
• W3128665037 hasConceptScore W3128665037C2778907293 @default.
• W3128665037 hasConceptScore W3128665037C501593827 @default.
• W3128665037 hasConceptScore W3128665037C502942594 @default.
• W3128665037 hasConceptScore W3128665037C71924100 @default.
• W3128665037 hasConceptScore W3128665037C86803240 @default.
• W3128665037 hasConceptScore W3128665037C89423630 @default.
• W3128665037 hasConceptScore W3128665037C98274493 @default.
• W3128665037 hasLocation W31286650371 @default.
• W3128665037 hasOpenAccess W3128665037 @default.
• W3128665037 hasPrimaryLocation W31286650371 @default.
• W3128665037 hasRelatedWork W2003594929 @default.
• W3128665037 hasRelatedWork W2004276527 @default.
• W3128665037 hasRelatedWork W2095815636 @default.
• W3128665037 hasRelatedWork W2100666999 @default.

• next